STOCK TITAN

[Form 4] GENIE ENERGY LTD Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Verona Pharma plc (VRNA) – Form 4 filing dated 08/05/2025

Non-executive director Mahendra Shah reported routine equity activity tied to previously granted restricted stock units (RSUs). On 08/01/2025, 24,000 Ordinary Shares (equivalent to 3,000 ADSs; eight Ordinary Shares per ADS) were acquired upon RSU vesting/settlement at $0 exercise price (code “M”). To cover statutory tax withholding, Shah executed a mandatory sell-to-cover of 3,608 Ordinary Shares (451 ADSs) at an average $13.1437 per Ordinary Share (code “S”).

Post-transaction holdings total 93,472 Ordinary Shares (11,684 ADSs) held directly, plus 72,000 RSUs that continue to vest 25% on each of 1 Aug 2025, 1 Nov 2025, 1 Feb 2026 and 1 May 2026, subject to continued service. No cash proceeds were realized from the RSU conversion itself; only the small portion sold for taxes generated proceeds.

The filing reflects normal insider tax-related activity rather than directional buying or selling. Ownership percentage and company fundamentals are essentially unchanged; therefore, the market impact is expected to be negligible.

Verona Pharma plc (VRNA) – Comunicazione Form 4 del 08/05/2025

Il direttore non esecutivo Mahendra Shah ha riportato un'attività azionaria di routine legata a unità azionarie vincolate (RSU) precedentemente assegnate. Il 01/08/2025 sono state acquisite 24.000 Azioni Ordinarie (equivalenti a 3.000 ADS; otto Azioni Ordinarie per ADS) in seguito al consolidamento/liquidazione delle RSU, con un prezzo di esercizio pari a $0 (codice “M”). Per coprire la ritenuta fiscale obbligatoria, Shah ha effettuato una vendita obbligatoria sell-to-cover di 3.608 Azioni Ordinarie (451 ADS) a un prezzo medio di $13,1437 per Azione Ordinaria (codice “S”).

Dopo la transazione, la detenzione totale è di 93.472 Azioni Ordinarie (11.684 ADS) detenute direttamente, oltre a 72.000 RSU che continueranno a maturare al 25% rispettivamente il 1° agosto 2025, 1° novembre 2025, 1° febbraio 2026 e 1° maggio 2026, subordinatamente alla continuazione del servizio. Non sono stati realizzati proventi in contanti dalla conversione delle RSU; solo la piccola porzione venduta per coprire le tasse ha generato ricavi.

La comunicazione riflette un'attività normale legata alle imposte degli insider, piuttosto che acquisti o vendite direzionali. La percentuale di proprietà e i fondamentali della società rimangono sostanzialmente invariati; pertanto, l'impatto sul mercato è previsto come trascurabile.

Verona Pharma plc (VRNA) – Presentación Formulario 4 con fecha 08/05/2025

El director no ejecutivo Mahendra Shah reportó una actividad accionaria rutinaria vinculada a unidades restringidas de acciones (RSUs) previamente otorgadas. El 01/08/2025 se adquirieron 24,000 Acciones Ordinarias (equivalente a 3,000 ADS; ocho Acciones Ordinarias por ADS) al consolidarse/liquidarse las RSUs con un precio de ejercicio de $0 (código “M”). Para cubrir la retención fiscal obligatoria, Shah ejecutó una venta obligatoria sell-to-cover de 3,608 Acciones Ordinarias (451 ADS) a un precio promedio de $13.1437 por Acción Ordinaria (código “S”).

Tras la transacción, las tenencias totales son de 93,472 Acciones Ordinarias (11,684 ADS) en propiedad directa, además de 72,000 RSUs que continuarán consolidándose en un 25% cada una el 1 de agosto de 2025, 1 de noviembre de 2025, 1 de febrero de 2026 y 1 de mayo de 2026, sujeto a la continuidad del servicio. No se obtuvieron ingresos en efectivo por la conversión de las RSU; solo una pequeña porción vendida para cubrir impuestos generó ingresos.

La presentación refleja una actividad fiscal habitual de los insiders más que compras o ventas direccionales. El porcentaje de propiedad y los fundamentos de la compañía permanecen esencialmente sin cambios; por lo tanto, se espera que el impacto en el mercado sea insignificante.

Verona Pharma plc (VRNA) – 2025년 8월 5일자 Form 4 제출

비상무이사 Mahendra Shah가 이전에 부여된 제한 주식 단위(RSU)와 관련된 일상적인 주식 활동을 보고했습니다. 2025년 8월 1일, RSU가 확정/정산됨에 따라 24,000 보통주(ADS 3,000주 상당; ADS당 8주 보통주)가 행사가격 $0(코드 “M”)으로 취득되었습니다. 법정 세금 원천징수를 위해 Shah는 의무적으로 3,608 보통주(451 ADS)를 평균 주당 $13.1437(코드 “S”)에 sell-to-cover 방식으로 매도했습니다.

거래 후 보유 주식은 직접 보유한 93,472 보통주(11,684 ADS)와 계속해서 2025년 8월 1일, 11월 1일, 2026년 2월 1일, 5월 1일에 각각 25%씩 확정되는 72,000 RSU입니다. 이는 계속 근무 조건에 따릅니다. RSU 전환 자체로는 현금 수익이 발생하지 않았으며, 세금 납부를 위해 소량 매도한 부분만 수익을 발생시켰습니다.

이번 제출은 내부자의 세금 관련 정상적인 활동을 반영한 것으로, 방향성 매수 또는 매도와는 무관합니다. 소유 지분과 회사의 기본 사항은 본질적으로 변함이 없으므로 시장에 미치는 영향은 미미할 것으로 예상됩니다.

Verona Pharma plc (VRNA) – Dépôt Formulaire 4 daté du 08/05/2025

Le directeur non exécutif Mahendra Shah a déclaré une activité boursière de routine liée à des unités d’actions restreintes (RSU) précédemment attribuées. Le 01/08/2025, 24 000 actions ordinaires (équivalant à 3 000 ADS ; huit actions ordinaires par ADS) ont été acquises lors de la levée/règlement des RSU à un prix d’exercice de 0 $ (code « M »). Pour couvrir la retenue d’impôt obligatoire, Shah a effectué une vente obligatoire sell-to-cover de 3 608 actions ordinaires (451 ADS) à un prix moyen de 13,1437 $ par action ordinaire (code « S »).

Après la transaction, la détention totale s’élève à 93 472 actions ordinaires (11 684 ADS) détenues directement, plus 72 000 RSU qui continueront de se libérer à raison de 25 % chacun les 1er août 2025, 1er novembre 2025, 1er février 2026 et 1er mai 2026, sous réserve de la poursuite du service. Aucun produit en espèces n’a été réalisé lors de la conversion des RSU ; seule la petite portion vendue pour couvrir les impôts a généré des recettes.

Le dépôt reflète une activité fiscale normale des initiés plutôt que des achats ou ventes directionnels. Le pourcentage de détention et les fondamentaux de la société restent essentiellement inchangés ; par conséquent, l’impact sur le marché est estimé comme négligeable.

Verona Pharma plc (VRNA) – Form 4 Einreichung vom 08.05.2025

Der nicht geschäftsführende Direktor Mahendra Shah meldete routinemäßige Aktienaktivitäten im Zusammenhang mit zuvor gewährten Restricted Stock Units (RSUs). Am 01.08.2025 wurden 24.000 Stammaktien (entsprechend 3.000 ADS; acht Stammaktien pro ADS) im Zuge der RSU-Vesting/Abwicklung zu einem Ausübungspreis von 0 $ (Code „M“) erworben. Zur Abdeckung der gesetzlichen Steuerabzüge führte Shah einen verpflichtenden Sell-to-Cover-Verkauf von 3.608 Stammaktien (451 ADS) zu einem durchschnittlichen Preis von 13,1437 $ pro Stammaktie (Code „S“) durch.

Nach der Transaktion beläuft sich der direkte Bestand auf 93.472 Stammaktien (11.684 ADS) sowie 72.000 RSUs, die weiterhin jeweils zu 25 % am 1. August 2025, 1. November 2025, 1. Februar 2026 und 1. Mai 2026 vesten, vorbehaltlich fortgesetzter Dienstzeit. Aus der RSU-Umwandlung selbst wurden keine Barauszahlungen erzielt; nur der kleine Anteil, der zur Steuerzahlung verkauft wurde, generierte Erlöse.

Die Meldung spiegelt eine normale, steuerbedingte Insider-Aktivität wider und keine richtungsweisenden Käufe oder Verkäufe. Der Eigentumsanteil und die Unternehmensgrundlagen bleiben im Wesentlichen unverändert; daher wird der Markteinfluss als vernachlässigbar eingeschätzt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting; small tax sale—neutral signal.

The Form 4 shows a standard RSU settlement for director Mahendra Shah. He converted 24k Ordinary Shares at zero cost and disposed of 3.6k shares solely to meet tax obligations, leaving his net position largely intact (-3.8% of new shares). Remaining 93.5k Ordinary Shares plus 72k unvested RSUs indicate continued alignment with shareholders. No new purchases or discretionary sales occurred, so I view the disclosure as not impactful to valuation or sentiment.

Verona Pharma plc (VRNA) – Comunicazione Form 4 del 08/05/2025

Il direttore non esecutivo Mahendra Shah ha riportato un'attività azionaria di routine legata a unità azionarie vincolate (RSU) precedentemente assegnate. Il 01/08/2025 sono state acquisite 24.000 Azioni Ordinarie (equivalenti a 3.000 ADS; otto Azioni Ordinarie per ADS) in seguito al consolidamento/liquidazione delle RSU, con un prezzo di esercizio pari a $0 (codice “M”). Per coprire la ritenuta fiscale obbligatoria, Shah ha effettuato una vendita obbligatoria sell-to-cover di 3.608 Azioni Ordinarie (451 ADS) a un prezzo medio di $13,1437 per Azione Ordinaria (codice “S”).

Dopo la transazione, la detenzione totale è di 93.472 Azioni Ordinarie (11.684 ADS) detenute direttamente, oltre a 72.000 RSU che continueranno a maturare al 25% rispettivamente il 1° agosto 2025, 1° novembre 2025, 1° febbraio 2026 e 1° maggio 2026, subordinatamente alla continuazione del servizio. Non sono stati realizzati proventi in contanti dalla conversione delle RSU; solo la piccola porzione venduta per coprire le tasse ha generato ricavi.

La comunicazione riflette un'attività normale legata alle imposte degli insider, piuttosto che acquisti o vendite direzionali. La percentuale di proprietà e i fondamentali della società rimangono sostanzialmente invariati; pertanto, l'impatto sul mercato è previsto come trascurabile.

Verona Pharma plc (VRNA) – Presentación Formulario 4 con fecha 08/05/2025

El director no ejecutivo Mahendra Shah reportó una actividad accionaria rutinaria vinculada a unidades restringidas de acciones (RSUs) previamente otorgadas. El 01/08/2025 se adquirieron 24,000 Acciones Ordinarias (equivalente a 3,000 ADS; ocho Acciones Ordinarias por ADS) al consolidarse/liquidarse las RSUs con un precio de ejercicio de $0 (código “M”). Para cubrir la retención fiscal obligatoria, Shah ejecutó una venta obligatoria sell-to-cover de 3,608 Acciones Ordinarias (451 ADS) a un precio promedio de $13.1437 por Acción Ordinaria (código “S”).

Tras la transacción, las tenencias totales son de 93,472 Acciones Ordinarias (11,684 ADS) en propiedad directa, además de 72,000 RSUs que continuarán consolidándose en un 25% cada una el 1 de agosto de 2025, 1 de noviembre de 2025, 1 de febrero de 2026 y 1 de mayo de 2026, sujeto a la continuidad del servicio. No se obtuvieron ingresos en efectivo por la conversión de las RSU; solo una pequeña porción vendida para cubrir impuestos generó ingresos.

La presentación refleja una actividad fiscal habitual de los insiders más que compras o ventas direccionales. El porcentaje de propiedad y los fundamentos de la compañía permanecen esencialmente sin cambios; por lo tanto, se espera que el impacto en el mercado sea insignificante.

Verona Pharma plc (VRNA) – 2025년 8월 5일자 Form 4 제출

비상무이사 Mahendra Shah가 이전에 부여된 제한 주식 단위(RSU)와 관련된 일상적인 주식 활동을 보고했습니다. 2025년 8월 1일, RSU가 확정/정산됨에 따라 24,000 보통주(ADS 3,000주 상당; ADS당 8주 보통주)가 행사가격 $0(코드 “M”)으로 취득되었습니다. 법정 세금 원천징수를 위해 Shah는 의무적으로 3,608 보통주(451 ADS)를 평균 주당 $13.1437(코드 “S”)에 sell-to-cover 방식으로 매도했습니다.

거래 후 보유 주식은 직접 보유한 93,472 보통주(11,684 ADS)와 계속해서 2025년 8월 1일, 11월 1일, 2026년 2월 1일, 5월 1일에 각각 25%씩 확정되는 72,000 RSU입니다. 이는 계속 근무 조건에 따릅니다. RSU 전환 자체로는 현금 수익이 발생하지 않았으며, 세금 납부를 위해 소량 매도한 부분만 수익을 발생시켰습니다.

이번 제출은 내부자의 세금 관련 정상적인 활동을 반영한 것으로, 방향성 매수 또는 매도와는 무관합니다. 소유 지분과 회사의 기본 사항은 본질적으로 변함이 없으므로 시장에 미치는 영향은 미미할 것으로 예상됩니다.

Verona Pharma plc (VRNA) – Dépôt Formulaire 4 daté du 08/05/2025

Le directeur non exécutif Mahendra Shah a déclaré une activité boursière de routine liée à des unités d’actions restreintes (RSU) précédemment attribuées. Le 01/08/2025, 24 000 actions ordinaires (équivalant à 3 000 ADS ; huit actions ordinaires par ADS) ont été acquises lors de la levée/règlement des RSU à un prix d’exercice de 0 $ (code « M »). Pour couvrir la retenue d’impôt obligatoire, Shah a effectué une vente obligatoire sell-to-cover de 3 608 actions ordinaires (451 ADS) à un prix moyen de 13,1437 $ par action ordinaire (code « S »).

Après la transaction, la détention totale s’élève à 93 472 actions ordinaires (11 684 ADS) détenues directement, plus 72 000 RSU qui continueront de se libérer à raison de 25 % chacun les 1er août 2025, 1er novembre 2025, 1er février 2026 et 1er mai 2026, sous réserve de la poursuite du service. Aucun produit en espèces n’a été réalisé lors de la conversion des RSU ; seule la petite portion vendue pour couvrir les impôts a généré des recettes.

Le dépôt reflète une activité fiscale normale des initiés plutôt que des achats ou ventes directionnels. Le pourcentage de détention et les fondamentaux de la société restent essentiellement inchangés ; par conséquent, l’impact sur le marché est estimé comme négligeable.

Verona Pharma plc (VRNA) – Form 4 Einreichung vom 08.05.2025

Der nicht geschäftsführende Direktor Mahendra Shah meldete routinemäßige Aktienaktivitäten im Zusammenhang mit zuvor gewährten Restricted Stock Units (RSUs). Am 01.08.2025 wurden 24.000 Stammaktien (entsprechend 3.000 ADS; acht Stammaktien pro ADS) im Zuge der RSU-Vesting/Abwicklung zu einem Ausübungspreis von 0 $ (Code „M“) erworben. Zur Abdeckung der gesetzlichen Steuerabzüge führte Shah einen verpflichtenden Sell-to-Cover-Verkauf von 3.608 Stammaktien (451 ADS) zu einem durchschnittlichen Preis von 13,1437 $ pro Stammaktie (Code „S“) durch.

Nach der Transaktion beläuft sich der direkte Bestand auf 93.472 Stammaktien (11.684 ADS) sowie 72.000 RSUs, die weiterhin jeweils zu 25 % am 1. August 2025, 1. November 2025, 1. Februar 2026 und 1. Mai 2026 vesten, vorbehaltlich fortgesetzter Dienstzeit. Aus der RSU-Umwandlung selbst wurden keine Barauszahlungen erzielt; nur der kleine Anteil, der zur Steuerzahlung verkauft wurde, generierte Erlöse.

Die Meldung spiegelt eine normale, steuerbedingte Insider-Aktivität wider und keine richtungsweisenden Käufe oder Verkäufe. Der Eigentumsanteil und die Unternehmensgrundlagen bleiben im Wesentlichen unverändert; daher wird der Markteinfluss als vernachlässigbar eingeschätzt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
JONAS HOWARD S

(Last) (First) (Middle)
C/O GENIE ENERGY LTD.
520 BROAD STREET

(Street)
NEWARK NJ 07102

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Genie Energy Ltd. [ GNE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class B Common Stock, $.01 par value per share 08/01/2025 F 7,105(1) D $20.1 721,638(2) D
Class B Common Stock, $.01 par value per share 08/03/2025 F 10,420(1) D $20.15 711,218(3) D
Class B Common Stock, $.01 par value per share 275,047 I By The Jonas Foundation
Class B Common Stock, $.01 par value per share 1,085,645 I By HSJ 2019 Remainder Trust
Class B Common Stock, $.01 par value per share 950,398 I By Debbie Y. Jonas 2018 Dynasty Trust
Class B Common Stock, $.01 par value per share 95,366 I By HSJ 2022 Annuity Trust I
Class A Common Stock, $.01 par value per share 1,574,326 I By Genie A Partners, L.P.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares withheld by the Issuer for tax purposes upon the vesting of Restricted Stock.
2. Consists of 530,709 shares held directly and 67,597 vested restricted shares of Class B common stock, 123,332 unvested restricted shares of Class B common stock, of which: (i) 36,666 shares shall vest on each of August 3, 2025 and February 10, 2026; and (ii) 25,000 shares shall vest on each of August 3, 2026 and August 2, 2027.
3. Consists of 530,709 shares held directly and 93,843 vested restricted shares of Class B common stock, 86,666 unvested restricted shares of Class B common stock, of which: (i) 36,666 shares shall vest on February 10, 2026; and (ii) 25,000 shares shall vest on each of August 3, 2026 and August 2, 2027.
Joyce J. Mason, by Power of Attorney 08/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Verona Pharma (VRNA) shares did Mahendra Shah acquire in this filing?

He acquired 24,000 Ordinary Shares (3,000 ADSs) through RSU settlement at $0 exercise price.

Why were 3,608 Verona Pharma shares sold on 08/01/2025?

The sale was a mandatory sell-to-cover transaction to satisfy tax withholding on the RSU vesting.

What is Mahendra Shah’s total direct ownership after the transactions?

He now holds 93,472 Ordinary Shares, equivalent to 11,684 ADSs.

How many restricted stock units remain unvested for the director?

Shah retains 72,000 RSUs that vest 25% each on 1 Aug 2025, 1 Nov 2025, 1 Feb 2026 and 1 May 2026.

Is this insider activity considered bullish or bearish for VRNA stock?

The filing is largely neutral; it reflects administrative tax-related activity, not discretionary buying or selling.
Genie Energy Ltd

NYSE:GNE

GNE Rankings

GNE Latest News

GNE Latest SEC Filings

GNE Stock Data

548.46M
20.85M
17.5%
35.2%
2.39%
Utilities - Regulated Electric
Electric & Other Services Combined
Link
United States
NEWARK